“…Thirteen of the 20 studies employed the research diagnostic criteria for TMD or diagnostic criteria for TMD 17 – 21 , 23 – 26 , 30 – 33 , while the remaining seven studies failed to specify a standardized and validated diagnostic method 22 , 27 – 29 , 34 – 36 . In 11 out of the 20 studies, BTX-A was injected into the masseter and temporal muscles 21 – 23 , 25 , 26 , 29 , 30 , 32 , 33 , 35 , 36 ; in four studies, BTX-A was injected into the masseter, temporal, and pterygoid muscles 17 , 24 , 28 , 34 ; in two studies, BTX-A was injected into the masseter muscle 18 , 31 ; and in three studies, BTX-A was injected into the lateral pterygoid muscles 19 , 20 , 27 . The total dose of BTX-A ranged from 15 to 150 U for each side, and most studies used a low dose of BTX-A (30–50 U for each side).…”